可降解涂层雷帕霉素洗脱支架(Tivoli支架)治疗冠状动脉性心脏病的疗效  

Sirolimus-eluting stent with biodegradable polymer coating in treatment of patients with coronary heart disease

作　　者：高力明[1] 游晓华[1] 徐荣良[1] 秦永文[1] 

机构地区：[1]第二军医大学附属长海医院心血管内科,上海200433

出　　处：《上海医学》2012年第3期203-205,共3页Shanghai Medical Journal

摘　　要：目的评价国产可降解涂层雷帕霉素洗脱支架(Tivoli支架)用于冠状动脉性心脏病(CHD)患者介入治疗的安全性和近期疗效。方法 2010年9—11月于第二军医大学附属长海医院心血管内科单一植入Tivoli支架的CHD患者167例。术后接受双联抗血小板治疗9个月,观察主要心血管不良事件(MACE)的发生情况,并在术后12个月复查冠状动脉造影。结果 223处靶血管病变共使用Tivoli支架267枚,植入支架成功率达100%。术后12个月冠状动脉造影随访结果显示,支架内再狭窄的发生率为1.9%(4/211),无1例发生MACE。结论 Tivoli支架治疗CHD是可行的,且具有良好的安全性和满意的近期临床效果。Objective To evaluate the safety and short-term effectiveness of sirolimus-eluting stents with biodegradable polymer coating （Tivoli stents made in China） in the treatment of patients with coronary heart disease （CHD）. Methods From September 2010 to November 2010, 167 CHD patients were treated by percutaneous coronary intervention （PCI） with Tivoli stents. All the patients received dual antiplatelet medication as clopidogrel and aspirin for 9 months postoperatively. The major adverse cardiac events （MACE） were observed. And angiography was performed 12 months after PCI. Results In 223 vascular lesions, 267 Tivoli stents were successfully implanted and the success rate was 100 %. Angiography showed that the incidence rate of in-stent restenosis was 1.9% （4/211）. No MACE happened during the follow-up. Conclusion The implantation of Tivoli stent is safe and effective for the CHD patients in the short term. （Shanghai Med J, 2012, 35： 203-205）

关 键 词：雷帕霉素 药物洗脱支架 经皮冠状动脉介入治疗 生物可降解涂层 

分 类 号：R541.4[医药卫生—心血管疾病]